Mechanisms of secondary resistance to imatinib in gastrointestinal stromal tumors / 国际肿瘤学杂志
Journal of International Oncology
;
(12): 936-939, 2010.
Artigo
em Chinês
| WPRIM
| ID: wpr-385637
ABSTRACT
Imatinib is an effective tyrosine kinase inhibitor, used in the treatment of advanced or inoperable gastrointestinal stromal tumors. Despite its efficacy, resistance is often developed among a portion of patients. Resistance to imatinib can be divided into primary and secondary resistance, with the latter becoming the focus of many recent researches. Research on the mechanisms of secondary resistance may lead to the identification of novel therapeutic strategies.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of International Oncology
Ano de publicação:
2010
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS